Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Wharton's jelly-derived mesenchymal stem cell intramuscular injection for Duchenne muscular dystrophy
IRCT20150206020981N5Phase 2Completed
- Sponsor
- SinaCell
- Start
- Jun 2023
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of wharton's jelly mesenchymal stromal cells in Duchenne muscular dystrophy (DMD), sponsored by SinaCell. Primary endpoints: Forced vital capacity, Muscular function and 1 more. Started Jun 2023; status: completed.
02
Drugs
wharton's jelly mesenchymal stromal cells
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on IRCT20150206020981N5.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20150206020981N5.